Arecor Therapeutics (AREC) Competitors GBX 52 -0.50 (-0.95%) As of 02/21/2025 09:59 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines AREC vs. ORPH, REDX, ETX, TRX, FUM, SBTX, COS, C4XD, DDDD, and POLBShould you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Futura Medical (FUM), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry. Arecor Therapeutics vs. Open Orphan Redx Pharma e-therapeutics Tissue Regenix Group Futura Medical SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Poolbeg Pharma Open Orphan (LON:ORPH) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Does the MarketBeat Community favor ORPH or AREC? Open Orphan and Arecor Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformOpen OrphanOutperform VotesNo VotesUnderperform Votes2100.00% Arecor TherapeuticsN/AN/A Which has stronger earnings and valuation, ORPH or AREC? Open Orphan has higher revenue and earnings than Arecor Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpen Orphan£34.71M0.00N/AN/AN/AArecor Therapeutics£6.04M3.25-£10.68M-£28.30-1.84 Do institutionals and insiders believe in ORPH or AREC? 44.1% of Arecor Therapeutics shares are held by institutional investors. 25.3% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to ORPH or AREC? In the previous week, Open Orphan had 1 more articles in the media than Arecor Therapeutics. MarketBeat recorded 1 mentions for Open Orphan and 0 mentions for Arecor Therapeutics. Open Orphan's average media sentiment score of 1.32 beat Arecor Therapeutics' score of 0.00 indicating that Open Orphan is being referred to more favorably in the media. Company Overall Sentiment Open Orphan Positive Arecor Therapeutics Neutral Is ORPH or AREC more profitable? Open Orphan has a net margin of 0.00% compared to Arecor Therapeutics' net margin of -176.89%. Open Orphan's return on equity of 0.00% beat Arecor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Open OrphanN/A N/A N/A Arecor Therapeutics -176.89%-118.67%-37.31% SummaryOpen Orphan beats Arecor Therapeutics on 6 of the 9 factors compared between the two stocks. Get Arecor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AREC vs. The Competition Export to ExcelMetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£19.63M£118.03M£5.84B£2.64BDividend YieldN/A3.69%4.75%4.98%P/E Ratio-1.843.2026.38162.45Price / Sales3.254,826.69435.33313,812.36Price / Cash5.0713.0138.0128.15Price / Book3.1447.077.645.16Net Income-£10.68M-£87.82M£3.19B£5.75B7 Day PerformanceN/A0.39%-2.12%-1.02%1 Month Performance-11.83%3.65%-0.44%-0.86%1 Year Performance-64.14%99.16%16.30%39.56% Arecor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARECArecor TherapeuticsN/AGBX 52-1.0%N/A-64.7%£19.63M£6.04M-1.8410Gap DownORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179Positive NewsREDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101News CoverageGap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295,000.00-450.0035Positive NewsHigh Trading VolumeTRXTissue Regenix GroupN/AGBX 57.35-2.0%N/A-31.6%£51.70M£31.98M-59.21120FUMFutura MedicalN/AGBX 14-1.9%N/A-68.4%£43.64M£8.68M-11.5512Negative NewsSBTXSkinBioTherapeuticsN/AGBX 18.50+2.1%N/A+96.2%£42.26M£1.56M-11.3811Gap UpCOSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718,000.00-1.08106POLBPoolbeg PharmaN/AGBX 4.80-5.0%N/A-64.1%£24.67MN/A-0.0112News CoverageGap Down Related Companies and Tools Related Companies Open Orphan Alternatives Redx Pharma Alternatives e-therapeutics Alternatives Tissue Regenix Group Alternatives Futura Medical Alternatives SkinBioTherapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives 4D pharma Alternatives Poolbeg Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:AREC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
